Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name LY3484356
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
LY3484356 LY 3484356|LY-3484356|SERD LY3484356|imlunestrant Hormone - Anti-estrogens 23 LY3484356 is a selective estrogen receptor degrader that binds to and causes the degradation of the estrogen receptor (ER), potentially leading to decreased ER signaling and antitumor activity (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 1050-1050).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04647487 Phase I LY3484356 A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2) Active, not recruiting USA | FRA | ESP | DEU | BEL 1
NCT04975308 Phase III Exemestane Abemaciclib + LY3484356 LY3484356 Fulvestrant A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 15
NCT04188548 Phase I Abemaciclib + LY3484356 LY3484356 Abemaciclib + LY3484356 + Trastuzumab Abemaciclib + Anastrozole + LY3484356 Abemaciclib + Exemestane + LY3484356 Alpelisib + LY3484356 Everolimus + LY3484356 Abemaciclib + Letrozole + LY3484356 A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) Recruiting USA | FRA | ESP | BEL 4
NCT05514054 Phase III Letrozole Anastrozole Exemestane Tamoxifen LY3484356 A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 24


Additional content available in CKB BOOST